Standard Biotools is trading 7.65% up at $0.70 in pre-market, most likely reflecting broader risk-on sentiment.
- No fresh company-specific announcement was identified for August 25, 2026.
- The latest update, August 5 earnings, reported $20.1 million in second-quarter revenue and continued progress toward the Treeline Biosciences merger.
- Nasdaq futures were up 0.81%, supporting a broader market explanation for the move.